Lumos Diagnostics

Lumos Diagnostics?(ASX: LDX) CEO and Managing Director, Doug Ward?will be presenting at the?HealthInvest?summit in Sydney on Wednesday, 2 April 2025. The event is hosted by?Morgans Financial Limited,?IR Department, and?Stockhead, with the aim of showcasing leading and emerging Australian health and life sciences companies.? ? The event is a unique opportunity for investors to hear from Doug about the most recent updates on Lumos’ development, manufacture and distribution of diagnostic technologies, to deliver actionable information, in real time, at the point-of-care.? ? Details: ????Date:?4:15pm, Wednesday, 2 April 2025 ???Location:?Morgans, Level 21, 88 Phillip Street, Sydney ???Register now:?https://lnkd.in/gSu2xbd9 #LDX #HealthInvest #Lumos #LDX?#innovation?#diagnostics?#pointofcare #HealthInvest #HealthcareInnovation #LifeSciences #ASX

Lumos Diagnostics is pleased to announce an agreement to expand the scope of work under its Development Agreement covering the new fetal fibronectin (fFN) test for leading women’s health company, Hologic, Inc. The expanded scope of work relates to Phase 3 of the Development Agreement, which focuses on delivery of the system prototype. This phase will now include incorporating additional hardware features into the proprietary reader technology, with an additional fee to Lumos of between US$0.6 – US$0.8 million. Lumos Diagnostics Managing Director, Doug Ward, said: "We are extremely pleased with the progress of the Hologic fFN project. Phase 2 of the project is progressing well and is expected to complete around April 2025, triggering the second of the Phase 2 milestone payments, worth US$0.3 million.[SD1]? In collaboration with the Hologic team, Phase 3 will now deliver a more feature rich product." ? Read the ASX release ?? https://lnkd.in/gnTvRu6b $LDX #LDX #Lumos #diagnostics #womenshealth #innovation

??? Investor Briefing | Monday 3 March at 1pm AEDT Lumos Diagnostics (ASX:LDX) has this week released its half yearly report for FY25, highlighting solid revenue growth, and significant progress across a number of pivotal commercial and development milestones. Join Lumos CEO and MD, Doug Ward, and Chief Financial Officer, Barrie Lambert, for an online investor briefing at 1:00pm AEDT on Monday 3 March. They will share an overview of the results and recent progress milestones, followed by a Q+A session. Register to attend ?? https://lnkd.in/gP56axBF $LDX #LDX #Lumos #pointofcare #diagnostics #innovation #healthcare #antimicrobialresistance #AMR #invest

?? ?????????????????? A recent Stockhead article by Nadine McGrath has highlighted Lumos' successful approach to business growth by leveraging strategic partnerships that drive innovation in point-of-care diagnostics, enabling us to expand our manufacturing capabilities and advance our platform development. Here's an excerpt: "?????????? ???????????????????? ?????????????? ?????????? ???????????????? ???????? ?????????????????? ?????????? ???????? ?????? ?? ?????????? ???????????????? ????????, ?????????? ???? ???????????????? ???????? ???????????????????? ???? ?????????????? ?????????? ???? ???????????????? ?????? ???????????????????????? ????????????????, ?????????????????? ?????? ????????-??????.? “?????? ???????????????????? ???? ???????? ???????? ?????????? ??????’?? ???????? ???? ???????????? ???? ?? ?????????????? ???????????????????? ???????? ?????? ?????????????????? ?????? ?????? ???????????? ?????????????? ???? ?????????????? ???????? ?? ?????????????? ?????????? ?????????????? ?????? ?????? ????????????????????, ???????????? ???????????????? ??????/???? ????????-?????? ???? ?????????????????? ???? ?????????? ??????????,” ?????? ????????." Take a look ?? https://lnkd.in/gp57yFvc $LDX #Lumos #LDX #pointofcare #diagnostics #healthcare #innovation

?? Australian Doctor ? General practitioners (GPs) routinely assess conflicting symptoms of respiratory illness in their patients - and on the balance of available information and clinical judgement, often prescribe antibiotics on the spot. Journalist Rachel Fieldhouse has written an article for Australian Doctor - ‘New point-of-care tests promise to pick the patients who actually need antibiotics' - featuring Lumos’ FebriDx? rapid point-of-care diagnostic test, which is now approved and ready to help in Australia. FebriDx? enables healthcare professionals to distinguish between bacterial infections and non-bacterial etiology, supporting informed decisions about antibiotic prescriptions. Lumos Non-Executive Chair, Sam Lanyon, was interviewed and reflected on Lumos’ consultation with the Australian medical community. “A fast, cost-effective point-of-care test would be useful to help them provide the evidence to a patient that they don’t need antibiotics and they’re not going to be effective,” he said. “In the Australian and US context, we had exactly the same feedback. [Doctors] all articulate the same problem.” See the article here: https://bit.ly/LDX_AusDoc $LDX #LDX #Lumos #innovation #diagnostics #pointofcare #AMR #antimicrobialresistance

Investor Webinar ? Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q2 FY25 quarterly performance. The presentation covers recent achievements including BARDA funding for clinical trials, progress on major partnerships, and updates on product development initiatives too. Take a look: https://lnkd.in/gyGAmicE $LDX #LDX #Lumos #innovation #diagnostics #pointofcare #AMR #antimicrobialresistance

2024 was a remarkable year of achievements for Lumos Diagnostics, and we're building on this momentum in the year ahead. Check out Stockhead TV for an exclusive look at our exciting plans and future direction ?? https://lnkd.in/gXXEUmAE $LDX #LDX #Lumos #pointofcare #medicaldevice #innovation

Take a look at this special report in Stockhead outlining Lumos' recent partnership announcement with MedPro, and the progress our Company is making to tackle the overuse of antibiotics. It's worth a read ?? https://lnkd.in/g_yXPHt4 $LDX #LDX #Lumos #pointofcare #medicaldevice #innovation

?? New Partnership Lumos Diagnostics has announced a partnership with MedPro Associates to provide national contract sales coverage for FebriDx? across hospital and primary care markets in the United States. MedPro's team of more than 60 territory representatives will support sales, training and in-servicing for FebriDx?, the only point-of-care diagnostic test to distinguish between bacterial and non-bacterial infections. Lumos CEO and Managing Director, Doug Ward, commented: "We are thrilled to be working alongside MedPro to bring our products to the US Market. Their familiarity with US healthcare markets coupled with their strong customer relationships and business development expertise makes them an excellent partner." Read the ASX release ?? https://lnkd.in/gm8-rGAS $LDX #LDX #Lumos #FDA #medicaldevice #pointofcare #invest #innovation #health #biotech #medtech #AMR